RECURRENT MYELODYSPLASTIC SYNDROME

This early-stage trial tests whether adding regorafenib to the standard venetoclax plus azacitidine regimen is safe and effective for adults with acute myeloid leukemia (AML) that has returned or not responded to prior treatment. About 20 participants will receive the combination…

This early-stage trial tests the safety and best dose of TAK-243 in about 42 adults with acute myeloid leukemia or myelodysplastic syndromes that have returned or are not responding to standard therapy. TAK-243 works by blocking enzymes that cancer cells need to grow. The study i…

This early-phase trial tests a new drug called uproleselan combined with standard chemotherapy (fludarabine and cytarabine) in children and teens with acute myeloid leukemia, myelodysplastic syndrome, or mixed phenotype acute leukemia that has returned or not responded to treatme…

This study tests a new drug, seclidemstat, combined with a standard treatment (azacitidine) for people with certain blood cancers (myelodysplastic syndromes and chronic myelomonocytic leukemia). The goal is to find the best dose and see if the combination can shrink or control th…

This study tests a new combination of three drugs (navitoclax, venetoclax, and decitabine) in about 6 adults with high-risk myelodysplastic syndrome (MDS) that came back or didn't respond to initial treatment. The goal is to find the safest dose and see if the combo can shrink or…

This early-phase study tests a combination of two drugs—ipilimumab (an immunotherapy that helps the immune system attack cancer) and decitabine (a chemotherapy drug)—in adults with myelodysplastic syndrome or acute myeloid leukemia that has returned or not responded to prior trea…

This study tests a combination of two drugs, azacitidine and quizartinib, for adults with myelodysplastic syndromes or related blood cancers that have specific gene changes (FLT3 or CBL). The goal is to find the best dose and see how well the drugs control the cancer. About 30 pe…

This study tests a combination of two drugs, venetoclax and azacitidine, in people with high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) that has returned or not responded to prior therapy. The goal is to find the best dose and see how well the c…

This study tests whether combining two immunotherapy drugs (nivolumab and ipilimumab) with a chemotherapy drug (azacitidine) can help people with myelodysplastic syndromes (MDS), a bone marrow disorder. About 99 adults with MDS, including those who have not responded to prior tre…

This study tests a specific schedule of chemotherapy drugs (busulfan and fludarabine) followed by a donor stem cell transplant for people with high-risk blood cancers like leukemia and lymphoma. After the transplant, a drug called cyclophosphamide is given to help prevent the don…

This study tests a drug called olaparib in adults whose acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) has returned or not responded to treatment and who have a specific change in the IDH gene. The drug works by blocking enzymes that cancer cells need to grow. The…

This early-stage trial tests a drug called DR-18 in 20 adults whose acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) has come back or persists after a stem cell transplant. DR-18 is a modified immune protein designed to boost the body's natural defenses against canc…